DEXCOM INC
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
DXCM$81.07+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
DexCom, Inc.
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (In millions, except par value data) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $917.7 | $606.1 |
| Short-term marketable securities | 1,081.0 | 1,973.3 |
| Accounts receivable, net | 1,216.1 | 1,005.7 |
| Inventory | 629.1 | 542.6 |
| Prepaid and other current assets | 189.4 | 173.7 |
| Total current assets | 4,033.3 | 4,301.4 |
| Property and equipment, net | 1,559.9 | 1,339.9 |
| Operating lease right-of-use assets | 77.4 | 62.8 |
| Goodwill | 24.2 | 22.8 |
| Intangibles, net | 70.8 | 103.4 |
| Deferred tax assets | 295.6 | 481.2 |
| Other assets | 278.7 | 173.0 |
| Total assets | $6,339.9 | $6,484.5 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,944.0 | $1,585.1 |
| Accrued payroll and related expenses | 169.2 | 112.0 |
| Current portion of long-term senior convertible notes | — | 1,204.4 |
| Short-term operating lease liabilities | 21.6 | 22.5 |
| Other current liabilities | 7.7 | 8.0 |
| Total current liabilities | 2,142.5 | 2,932.0 |
| Long-term senior convertible notes | 1,240.9 | 1,237.0 |
| Long-term operating lease liabilities | 73.4 | 65.0 |
| Other long-term liabilities | 137.1 | 147.9 |
| Total liabilities | 3,593.9 | 4,381.9 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value, 800.0 million shares authorized; 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025; and 408.9 million and 390.7 million shares issued and outstanding, respectively, at December 31, 2024 | 0.4 | 0.4 |
| Additional paid-in capital | 2,281.5 | 2,093.8 |
| Accumulated other comprehensive income (loss) | 115.0 | (8.0) |
| Retained earnings | 2,433.9 | 1,597.6 |
| Treasury stock, at cost; 25.9 million shares at December 31, 2025 and 18.2 million shares at December 31, 2024 | (2,084.8) | (1,581.2) |
| Total stockholders’ equity | 2,746.0 | 2,102.6 |
| Total liabilities and stockholders’ equity | $6,339.9 | $6,484.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.